Biotech Research Collaboration Agreement Checklist: 12 Terms to Address Before Work Begins

What should a biotech research collaboration agreement include?

It should define the research plan, contributions, funding, materials, data, background IP, ownership of results and inventions, licenses, patent decisions, confidentiality, publication, compliance, governance, risk allocation, duration, termination, and continuing rights.

The right agreement depends on what the parties will actually exchange and do. NIH resources distinguish among confidential disclosure agreements, material transfer agreements, data-use or data-transfer arrangements, research collaboration agreements, cooperative research and development agreements, clinical trial agreements, and licenses.

A short form designed only to transfer a reagent may be inadequate when both teams will design experiments, create inventions, exchange confidential data, or pursue commercialization. Map the scientific and commercial workflow first, then select and draft the legal structure around it.

1. Is the research plan specific enough to manage the collaboration?

Attach a plan describing objectives, protocols, work packages, responsible investigators, deliverables, timelines, decision points, dependencies, and criteria for completion or expansion.

• Identify each party’s personnel, facilities, equipment, materials, data, and funding contributions.
• Distinguish committed work from optional future phases.
• Define how protocol changes, failed experiments, delays, and additional work are approved.
• Resolve inconsistencies among the agreement, research plan, budget, protocols, and other transfer documents.

2. Which materials and data may be transferred, used, and shared?

Define original materials, progeny, derivatives, modifications, samples, data sets, metadata, results, and permitted recipients, locations, purposes, transfers, retention, return, and destruction.

Restrictions should reflect the nature of the material or data. Address human use, clinical or diagnostic use, animal research, biosafety, export, privacy, data security, and onward transfer where relevant. If a material transfer agreement or data-use agreement will operate alongside the collaboration agreement, establish which document controls each issue.

3. What background IP does each party bring to the project?

Identify material pre-existing patents, know-how, data, software, methods, materials, and third-party rights, then grant only the licenses needed to perform the research.

• Use a schedule or clear identification process rather than a vague reference to all prior technology.
• State whether background rights are licensed only for research or also for commercialization.
• Disclose restrictions that could limit use of results or future licensing.
• Avoid language that unintentionally transfers ownership of a party’s platform or core technology.

4. Who owns research results, data, improvements, and inventions?

Define each category and establish ownership rules based on inventorship, creation, subject matter, contribution, or another agreed allocation, including treatment of jointly created results.

Patent inventorship is a legal determination and should not be replaced casually with a contractual label. The agreement can allocate ownership and licenses, but it should also create a process for identifying inventions, preserving records, resolving disagreements, and executing assignments or other documents required by the agreed structure.

5. What commercialization or license rights follow from the collaboration?

State whether a party receives an automatic license, an option to negotiate, a right of first negotiation, field-limited rights, exclusivity, or no commercial rights beyond the research project.

• Define option periods, notice, diligence, milestones, royalties, sublicensing, territory, field, and reservation of rights.
• Address improvements and combinations with each party’s background technology.
• Confirm the granting party has authority under existing university, government, investor, or license obligations.
• Explain what happens if the parties cannot agree on later license terms.

6. Who decides whether to file, prosecute, maintain, or abandon patents?

Create a process for invention disclosure, filing decisions, counsel selection, cost allocation, review, foreign filings, maintenance, abandonment, enforcement, and cooperation.

Patent timing must be coordinated with publications, presentations, abstracts, grant reports, and other disclosures. If one party declines to pursue protection, specify whether the other may do so and what ownership, reimbursement, or license consequences follow.

7. How should publication review protect patent and confidentiality interests?

Permit scientific publication subject to a defined advance-review period for removing confidential information and a limited delay to prepare patent filings.

The review process should include manuscripts, abstracts, posters, talks, preprints, and public data releases where relevant. Set clear deadlines and avoid an indefinite veto. Also address attribution, authorship standards, use of names, acknowledgments, and disputes about scientific interpretation.

8. Does confidentiality cover laboratory and commercial information?

Define confidential information, marking and identification, permitted recipients and uses, required safeguards, exclusions, compelled disclosure, incident response, and survival periods.

• Coordinate with any earlier confidentiality agreement and identify which terms survive or are replaced.
• Address disclosures to employees, students, contractors, affiliates, advisers, funders, and regulators.
• Protect trade secrets for as long as they remain trade secrets when appropriate.
• Establish secure methods for exchanging sensitive data, protocols, and unpublished results.

9. Which research, privacy, safety, and regulatory duties apply?

Allocate responsibility for approvals, consents, protocols, permits, biosafety, human and animal research, privacy, data security, export controls, laboratory standards, records, and regulatory communications.

The agreement should not imply that one party’s approval covers the other party’s activities. Identify which institution or company is responsible for each authorization and what evidence must be exchanged before work or transfer begins. For regulated development, address access to records and cooperation needed for submissions, inspections, safety reporting, or product support.

10. How will milestones, budgets, and scientific decisions be governed?

Define payment timing, eligible costs, invoicing, records, milestone acceptance, committee authority, meeting cadence, escalation, tie-breaking, and amendment procedures.

• Separate scientific coordination from decisions that change legal rights or budgets.
• Require written approval for material scope, funding, timeline, or resource changes.
• Identify project managers and authorized representatives for formal notices.
• Use an escalation path that does not leave research teams negotiating contract amendments informally.

11. Are warranties, liability, indemnity, and insurance suited to experimental work?

Address authority, condition of materials, experimental risk, legal compliance, third-party claims, misuse, injury, data or confidentiality incidents, liability limits, defense control, and relevant insurance.

Research materials and results are often provided without performance guarantees, but risk should still be allocated deliberately. Consider who controls the conduct giving rise to a claim, whether human or clinical use is prohibited, and how the provisions interact with institutional policies, sovereign immunity, or other legal constraints.

12. What happens to ongoing work, materials, data, and rights at termination?

Define termination triggers, notice, wind-down, final payments, disposition of samples and data, continuing experiments, publication, regulatory records, accrued rights, licenses, confidentiality, and transition assistance.

A collaboration may end before the science does. Decide whether active studies may finish, whether either party can use existing results, who preserves required records, and whether commercial options or licenses survive. The agreement should also address effects of investigator departure, loss of funding, safety concerns, or inability to obtain approvals.

When is an MTA different from a research collaboration agreement?

An MTA generally governs transfer and research use of proprietary materials without a planned scientific collaboration, while a collaboration agreement addresses joint work, contributions, results, governance, and related IP rights.

Projects may require more than one document, but overlapping terms should be reconciled. NIH guidance notes that an MTA ordinarily does not grant a commercial license or option, while a CRADA or another collaboration structure may address future rights in resulting inventions.